A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 05 Sep 2019 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 05 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.